Arsenic Trioxide and Dexamethasone in Treating Patients With Recurrent or Refractory Stage II or Stage III Multiple Myeloma
CTI 1060: A Phase II Clinical Trial of Arsenic Trioxide and Dexamethasone as Therapy for Relapsed or Refractory Multiple Myeloma
Sponsor: CTI BioPharma
Terminated
This trial was terminated. No reason was provided.
Other terminated trials from CTI BioPharma
Other Multiple Myeloma and Plasma Cell Neoplasm trials with similar outcome
Listed as NCT00017069, this PHASE2 trial focuses on Multiple Myeloma and Plasma Cell Neoplasm and remains terminated or withdrawn. Sponsored by CTI BioPharma, it has been updated 6 times since 2001, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Nov 2020 — Jan 2021 [monthly]
Terminated PHASE2
Status: Unknown Status → Terminated
-
Jun 2018 — Nov 2020 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Feb 2001
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CTI BioPharma
- National Cancer Institute (NCI)
For direct contact, visit the study record on ClinicalTrials.gov .